GlassScriptPhysician profile
Michelle Pata
NPI 1427545151
$1,712.62
in general payments reported to CMS, 2019-2025
25 companies · $597 in 2025
The $597 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $149 · 2023: $281 · 2024: $686 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,563.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $293.52 | 2022-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $287.68 | 2022-2025 | |
| Novo Nordisk INC | $218.02 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $209.94 | 2024-2025 | Spravato |
| Abbott Laboratories | $66.70 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $62.82 | 2022-2025 | |
| Inspire Medical Systems, INC. | $57.52 | 2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $52.39 | 2025 | Abilify Maintena, Abilify Asimtufii |
| Ironshore Pharmaceuticals INC. | $44.43 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.31 | 2022-2023 | Trintellix |
| Glaxosmithkline, LLC. | $42.93 | 2023-2025 | Shingrix, Arexvy |
| Exact Sciences Corporation | $39.13 | 2023 | Cologuard Collection Kit |
| Corcept Therapeutics | $36.67 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $28.25 | 2024 | Breztri, Airsupra |
| Galderma Laboratories, L.P. | $27.55 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $26.59 | 2025 | Dexcom G6 Transmitter |
| Revance Therapeutics, INC. | $23.47 | 2024 | Daxxify |
| Scpharmaceuticals INC. | $23.31 | 2025 | |
| Braeburn INC. | $22.19 | 2024 | Brixadi |
| Astellas Pharma US INC | $21.01 | 2024 | Veozah |
| Alkermes, INC. | $18.70 | 2025 | Aristada, Lybalvi |
| Currax Pharmaceuticals LLC | $17.59 | 2023 | Contrave, Onzetra Xsail |
| Medtronic, INC. | $17.12 | 2023 | Closurefast |
| Acella Pharmaceuticals, LLC | $16.93 | 2023 | NP Thyroid 60 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.85 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Pata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.